Immunological hormone atrophy by gonadotropin-based drug

Area of Science:

• Toxicology
• Pharmacology
• Reproductive Biology

Background:

• Luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin A (LHRH-PE40) and its modified form (mLHRH-PE40) are anti-tumour agents.
• The potential toxicity of these chimeric proteins on the male reproductive system requires thorough investigation.

Purpose of the Study:

• To evaluate the toxicity of LHRH-PE40 and mLHRH-PE40 on the male genital tract in a rat model.
• To determine the influence of drug delivery route and drug modification on potential adverse effects.

Main Methods:

• Male rats were administered LHRH-PE40 or mLHRH-PE40 via intravenous or intraperitoneal routes for 12 weeks.
• Serum and testes were analyzed for anti-LHRH antibodies, testosterone levels, and testicular morphology.
• ELISA and radioimmunoassay were employed for detection and quantification.

Main Results:

• Intraperitoneal LHRH-PE40 administration led to increased anti-LHRH antibody titers, decreased serum testosterone, and significant testicular atrophy.
• Intravenous administration of either LHRH-PE40 or mLHRH-PE40 did not result in these adverse effects.
• The observed testicular changes were linked to the LHRH component and influenced by the route of administration.

Conclusions:

• Testicular atrophy associated with LHRH-PE40 is likely mediated by anti-LHRH antibodies.
• Drug delivery route significantly impacts the immunogenicity and toxicity of LHRH-PE40.
• Sequence modification (mLHRH-PE40) did not alter the toxicity profile when administered intravenously.